206 related articles for article (PubMed ID: 27984005)
1. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Bangalore S; Davis BR; Cushman WC; Pressel SL; Muntner PM; Calhoun DA; Kostis JB; Whelton PK; Probstfield JL; Rahman M; Black HR;
Am J Med; 2017 Apr; 130(4):439-448.e9. PubMed ID: 27984005
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
[TBL] [Abstract][Full Text] [Related]
3. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
[TBL] [Abstract][Full Text] [Related]
5. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
[TBL] [Abstract][Full Text] [Related]
6. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
[TBL] [Abstract][Full Text] [Related]
7. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
Wang SY; Hanna JM; Gongal P; Onuma OK; Nanna MG
Am Heart J; 2022 Dec; 254():30-34. PubMed ID: 35932912
[TBL] [Abstract][Full Text] [Related]
8. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
Juraschek SP; Simpson LM; Davis BR; Beach JL; Ishak A; Mukamal KJ
Hypertension; 2019 Oct; 74(4):1033-1040. PubMed ID: 31476905
[TBL] [Abstract][Full Text] [Related]
9. Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial.
Yamal JM; Martinez J; Osani MC; Du XL; Simpson LM; Davis BR
JAMA Netw Open; 2023 Dec; 6(12):e2344998. PubMed ID: 38048133
[TBL] [Abstract][Full Text] [Related]
10. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Grimm RH; Davis BR; Piller LB; Cutler JA; Margolis KL; Barzilay J; Dart RA; Graumlich JF; Murden RA; Randall OS;
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):466-74. PubMed ID: 19751458
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Sundström J; Lind L; Nowrouzi S; Hagström E; Held C; Lytsy P; Neal B; Marttala K; Östlund O
JAMA; 2023 Apr; 329(14):1160-1169. PubMed ID: 37039792
[TBL] [Abstract][Full Text] [Related]
12. Association of Blood Pressure Measurements With Peripheral Artery Disease Events.
Itoga NK; Tawfik DS; Lee CK; Maruyama S; Leeper NJ; Chang TI
Circulation; 2018 Oct; 138(17):1805-1814. PubMed ID: 29930023
[TBL] [Abstract][Full Text] [Related]
13. Effect of antihypertensive agents on sleep apnea and ambulatory blood pressure in patients with hypertension: A randomized controlled trial.
Cichelero FT; Fuchs SC; Jorge JA; Martinez D; Oliveira GPF; Lucca MB; Oliveira ACT; Fuchs FD
Sleep Med; 2024 Jul; 119():417-423. PubMed ID: 38781664
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER-Prevention Randomized Clinical Trial.
Fuchs SC; Poli-de-Figueiredo CE; Figueiredo Neto JA; Scala LC; Whelton PK; Mosele F; de Mello RB; Vilela-Martin JF; Moreira LB; Chaves H; Mota Gomes M; de Sousa MR; Silva RP; Castro I; Cesarino EJ; Jardim PC; Alves JG; Steffens AA; Brandão AA; Consolim-Colombo FM; de Alencastro PR; Neto AA; Nóbrega AC; Franco RS; Sobral Filho DC; Bordignon A; Nobre F; Schlatter R; Gus M; Fuchs FC; Berwanger O; Fuchs FD
J Am Heart Assoc; 2016 Dec; 5(12):. PubMed ID: 27965209
[TBL] [Abstract][Full Text] [Related]
15. Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended.
Du XL; Simpson LM; Tandy BC; Bettencourt J; Davis BR
Int J Hypertens; 2021; 2021():2261144. PubMed ID: 34925915
[TBL] [Abstract][Full Text] [Related]
16. Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke: A Secondary Analysis of a Randomized Clinical Trial.
Ishani A; Hau C; Cushman WC; Leatherman SM; Lew RA; Glassman PA; Taylor AA; Ferguson RE
JAMA Netw Open; 2024 May; 7(5):e2411081. PubMed ID: 38743423
[TBL] [Abstract][Full Text] [Related]
17. Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
Gupta A; Whiteley WN; Godec T; Rostamian S; Ariti C; Mackay J; Whitehouse A; Janani L; Poulter NR; Sever PS;
Eur Heart J; 2024 Apr; 45(13):1159-1169. PubMed ID: 38291599
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT).
Vakil D; Zinonos S; Kostis JB; Dobrzynski JM; Cosgrove NM; Moreyra AE; Kostis WJ
J Clin Hypertens (Greenwich); 2021 Jul; 23(7):1335-1343. PubMed ID: 34076333
[TBL] [Abstract][Full Text] [Related]
19. Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.
Agarwal R; Cramer AE; Balmes-Fenwick M; Sinha AD; Ouyang F; Tu W
Am J Nephrol; 2020; 51(7):542-552. PubMed ID: 32663820
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Shuster JE; Bleske BE; Dorsch MP
Vasc Health Risk Manag; 2012; 8():381-7. PubMed ID: 22745562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
